免疫检查点抑制剂在晚期肝细胞肝癌治疗中的研究及应用

Research and application of immunological checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

晚期肝细胞肝癌(hepatocellular carcinoma,HCC)的综合治疗正在迅速发展,但主要集中于多靶点的酪氨酸激酶抑制剂治疗,虽已显示出优于最佳支持性治疗的生存优势,但出现有效率提高不明显、易耐药的问题,需开发新的治疗方法改变目前治疗现状。大量研究表明,机体免疫反应与HCC的发生、发展有密切关系。免疫检查点抑制剂通过增强免疫系统功能,发挥抗肿瘤效应,并已在晚期HCC前期临床研究中取得疗效。本文就近年关于免疫检查点抑制剂在HCC治疗中的研究及应用作一概述。

Comprehensive treatment for advanced hepatocellular carcinoma (HCC) evolving rapidly, mainly focuses on multi-target tyrosine kinase inhibitor therapy, although it has shown superior survival advantages over optimal supportive care, there is a problem that the efficiency is not obvious and the drug resistance is easy to develop. It is necessary to develop new treatment methods to change the current treatment status. A large number of studies have shown that the body’s immune response is closely related to the occurrence and development of HCC. Immunological checkpoint inhibitors have exerted anti-tumor effects by enhancing the function of the immune system, and have achieved therapeutic effects in advanced clinical studies of advanced HCC. This article reviewed recent research and application of immunological checkpoint inhibitors in the treatment of advanced HCC.